Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. OABI
OABI logo

OABI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy OmniAb Inc (OABI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.990
1 Day change
2.05%
52 Week Range
3.340
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

OmniAb Inc (OABI) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the stock shows some positive technical momentum in the pre-market, the company's financial performance and recent earnings report indicate significant challenges, including declining revenue and negative EPS. Additionally, there are no strong trading signals or positive catalysts to justify immediate action.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 81.155, suggesting the stock is overbought. The pre-market price of $2.04 is approaching resistance levels (R1: 1.984, R2: 2.076), which could limit further upside in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
10

Positive Catalysts

  • The company has increased its partner count and introduced the OmniUltra platform, which could support long-term growth.

Neutral/Negative Catalysts

  • Financial metrics show declining revenue, gross margin, and EPS, signaling operational challenges.

Financial Performance

In Q4 2025, revenue dropped to $8.4 million from $10.8 million YoY, and the company reported a GAAP EPS of -$0.11. For 2025/Q3, revenue decreased by 46.33% YoY, gross margin dropped significantly to -45.47%, and EPS fell by 12.50% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No specific analyst rating or price target changes are provided for OABI. Wall Street sentiment appears neutral, with no significant hedge fund or insider trading activity.

Wall Street analysts forecast OABI stock price to rise
6 Analyst Rating
Wall Street analysts forecast OABI stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.950
sliders
Low
3
Averages
6.8
High
11
Current: 1.950
sliders
Low
3
Averages
6.8
High
11
Craig-Hallum
Buy
downgrade
$10 -> $7
AI Analysis
2025-11-05
Reason
Craig-Hallum
Price Target
$10 -> $7
AI Analysis
2025-11-05
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on OmniAb to $7 from $10 and keeps a Buy rating on the shares. The firm notes the company reported several positive developments this quarter, driven by strong business momentum and a growing network of 104 active partners. Additionally, Craig-Hallum believes that the launch of OmniUltra, following last quarter's introduction of the xPloration Partner Access Program, should facilitate the development of new classes of biologically derived peptide therapeutics and this innovation will drive further partnerships.
RBC Capital
Conor McNamara
Buy
Maintains
$7 → $4
2025-03-27
Reason
RBC Capital
Conor McNamara
Price Target
$7 → $4
2025-03-27
Maintains
Buy
Reason
RBC Capital lowered the firm's price target on OmniAb to $4 from $7 and keeps an Outperform rating on the shares. The company provided lower than expected FY25 revenue guidance, though the outlook is prudent and de-risks lumpy contributions due to its partner's program progression, the analyst tells investors in a research note. RBC adds that its takeaways from OmniAb Q4 include continued program growth with healthy end markets and its view that FY25 revenue guide is achievable with lower cash spend.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OABI
Unlock Now

People Also Watch